MB-JXR @EC2603A

Huachang Securities Issues Report Forecasting Jin Xin Reproductive's 2025-2027 Performance

HRC Investment Reduces Holdings in JSR International by 8.63 million shares

Jin Xin Reproductive Reports Mid-Year Loss, Fertility Industry Faces Challenges

CICC Downgrades JSR Fertility's Profit Forecast but Maintains 'Outperform Industry' Rating

Jin Xin Reproductive Reports Q1 2025 Revenue Drop; JPMorgan Cuts Rating

Dong Yang Increases Holdings in JSR Holdings

Jin Xin Reproductive Releases Half-Year Report: Revenue Decreases, Shareholder Loss Widens

JXR released FY2025 Q1 earnings on August 25 (BJT), actual revenue HKD 690.02 M, actual EPS HKD -0.2088

JXR released FY2025 Semi-Annual Earnings on August 25 After-Market (BJT), actual revenue HKD 1.395 B (forecast HKD 1.478 B), actual EPS HKD -0.4222 (forecast HKD 0.0547)

JXR released FY2025 Q2 earnings on August 25 After-Market (BJT), actual revenue HKD 705.19M, actual EPS HKD -0.2134

JXR to Release FY2025 Q2 Earnings on August 25 After-Market (BJT)

JinXin Reproductive Expected to Report Up to RMB 1.09 Billion Loss in H1 2025

Jin Xin Reproductive Adjusts Nomination Committee Members

Jin Xin Reproductive's Stock Price Rises, Significant Achievements in Reproductive Health Business

Jinxin Reproductive Medicine's Stock Price Rises Over 7% Due to Government Childbirth Policies

JXR released FY2024 9 Months Earnings on March 28 (BJT) with actual revenue of 2.316 B HKD and EPS of 0.0923 HKD

JXR released FY2024 Q3 earnings on March 28 (BJT), actual revenue 758.09 M HKD, actual EPS 0.0167 HKD

JXR released FY2024 annual earnings on March 28 After-Market (BJT), actual revenue 3.043 B HKD (forecast 3.248 B HKD), actual EPS 0.1082 HKD (forecast 0.1575 HKD)

JXR released FY2024 Q4 earnings on March 28 After-Market (BJT), actual revenue 727.59 M HKD, actual EPS 0.0161 HKD

National Health Commission Issues Notification for 2025 Population Quality Development Research, Hong Kong Stocks Decline, Fertility-Related Stocks Generally Fall

GUANZE MEDICAL

PCPD

STARCOIN GROUP

HUILI RES

TIMES UNI GP

MANY IDEA CLOUD

WALNUT CAP

SILKWAVE INC

HUA LIEN INT'L

WAI CHUN GROUP

159316

512290

159570

01951

Goldman Sachs report indicates that the mainland healthcare sector will continue to be strong, but investors need to pay attention to the value of the R&D pipeline. Outperformance depends on key data and earnings visibility. Positive on CDMO companies, upgrading WuXi AppTec and WUXI XDC ratings to "Buy." A selective strategy is recommended for biotech and pharmaceutical companies, recommending SKB BIO-B, HENLIUS, and HANSOH PHARMA. The medical device sector maintains a neutral stance, recommending ANGELALIGN and WEIGAO GROUP. A cautious attitude is taken towards the medical services sector, downgrading HYGEIA HEALTH and JXR ratings

AASTOCKS

E Fund Hang Seng SCHK Innovative Drug ETF

Guotai CSI Bio-medicine ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

HANSOH PHARMA

ChinaAMC SSE Health Care ETF Initiating Fund

Penghua CSI HK Connect Health Care Composite ETF

SKB BIO-B

ChinaAMC SSE STAR Biology and Medicine ETF

KELUN PHARMA

HENLIUS

WEIGAO GROUP

China Southern Hang Seng Biotech ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Hwabao WP CSI Pharmaceuticals ETF

Yinhua CSI Innovative Drugs Industry ETF

Bosera Hang Seng Health Care ETF(QDII)

China Merchants CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

HYGEIA HEALTH

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Penghua SSE STAR Biology and Medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

WuXi AppTec

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ANGELALIGN

Dacheng CSI All Share Health Care Equipment and Services ETF

Hwabao WP CSI Medical Service ETF

E Fund CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

E Fund CSI 300 Health Care ETF

WUXI XDC

Ping An CSI Medicine and Medical Device Innovation ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

WUXI APPTEC

Bosera Hang Seng SCHK Innovative Drug Select ETF

Goldman Sachs: The mainland medical sector will rely more on data and profit visibility this year, optimistic about CDMO companies

In Las Vegas, the latest office of HRC Fertility, overseen by Dr. Bradford Kolb, is set to offer top-tier fertility services, focusing on patient needs and inclusivity. This expansion will provide Nevada residents access to cutting-edge fertility treatments and expert care.

Unusual Whales

HRC Fertility expands to Las Vegas with new office led by Dr. Bradford Kolb, offering world-class fertility care.

In a report released yesterday, from CICC maintained a Buy rating on Jinxin Fertility Group Ltd., with a price target of HK$3.50.Claim 50% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Jinxin Fertility Group Ltd. with a HK$3.50 average price target.

Tip Ranks

CICC Remains a Buy on Jinxin Fertility Group Ltd. (1951)

JXR released data showing that the number of in vitro fertilization (IVF) treatments in the fourth quarter of 2025 was 7,004, an increase of 12% year-on-year. Despite a strong performance in the fourth quarter, the total number of IVF treatments for the year still declined by 1.4% to 28,039. The IVF treatments at the Chengdu flagship center rose by 1.3% to 14,070, while overseas business fell by 6.9% to 4,235. On Tuesday, the stock price slightly increased to HKD 2.50, down about 5% over the past 52 weeks

BambooWorks

Brief News: Although there are improvements in the fourth quarter data, JXR's annual business still fell by 1.4%

JXR (1951.HK) has recently experienced continuous capital outflow, and the MACD death cross structure indicates a bearish short-term trend. The stock price has been declining and is currently near the previous low support zone. Active buying is weak, and existing funds are mostly reducing positions to manage risks. The intraday price fluctuations have narrowed, and the main force's short-term participation has decreased, with defensive sentiment significantly rising. If there is an influx of incremental capital today, combined with a market sentiment recovery, there may be a tentative rebound; otherwise, the weak oscillation will continue. From a fundamental perspective, short-term growth expectations are average, and the unstable external market environment makes it difficult for capital to perform. Short-term operations should be defensive, focusing on technical rebound signals or market anomalies, and avoid blindly increasing positions against the trend. Considering both fundamentals and technical patterns, it is recommended to remain patient and wait for clearer opportunities

Technical Forecast

Morning Trend | JXR's capital withdrawal, is defensive sentiment intensifying under weak fluctuations?

JXR announced that, effective October 31, 2025, Ms. Zhai Yangyang will resign as the co-company secretary of the company, and Ms. Wu Xiuwai will resign as the co-company secretary and authorized representative. Zhai Yangyang is resigning for personal career development, while Wu Xiuwai is resigning due to other work arrangements. Ms. Zhong Manna will be appointed as the company secretary and authorized representative effective October 31, 2025

Zhitong

JXR: Zhong Manna has been appointed as the company secretary and authorized representative

In the nine months ending September 30, 2025, JXR significantly increased the number of IVF egg retrieval cycles, with the overall decline narrowing from -8.3% to -5.2%. The decline at the Chengdu hospital decreased from -6.1% to -1.9%, while the Shenzhen hospital's improvement was slow due to relocation plans. The decline in the number of IVF cycles in the U.S. market was in line with expectations due to the postponement of legislation. The company remains confident in the industry's prospects and future growth, benefiting from industry fundamentals, policy support, and continuous efforts

In the first three quarters, JXR made significant progress in the number of egg retrieval cycles in vitro fertilization (IVF)

According to the latest information from the Hong Kong Stock Exchange, on October 15th, Executive Director Dong Yang increased his holdings in JXR by 500,000 shares at a price of HKD 2.56 per share, totaling HKD 1.28 million. After the increase, the latest number of shares held is approximately 13.373 million, with a latest holding ratio of 0.48%

Executive Director Dong Yang increased his holdings in JXR by 500,000 shares at a price of HKD 2.56 per share

JXR's board of directors recommends adopting the 2025 share plan, which requires shareholder approval. The plan aims to align the long-term interests of directors and key employees with the company's interests, incentivizing them to drive company growth. The plan includes granting 137,235,000 stock options to management, as well as granting 2.4 million stock options and 1.2 million restricted shares to non-executive grantees

JXR recommends adopting the 2025 share plan

JXR announced that Fang Min resigned as a non-executive director and member of related committees, and Chen Shuyun was appointed as a non-executive director and member of various committees, with the appointment effective from the date of the announcement

JXR: Chen Shuyun has been appointed as a non-executive director

Huachuang Securities maintains a "Recommended" rating for JXR, with a target price of HKD 3.23. In 2025, the company's revenue is expected to be RMB 1.289 billion, a year-on-year decrease of 10.7%, with a net loss of RMB 1.04 billion and an adjusted net profit of RMB 82 million, a year-on-year decrease of 68.3%. Despite the pressure on revenue, the industry's penetration rate is expected to accelerate due to medical insurance and fertility subsidy policies. Revenue is projected to be RMB 2.602 billion, RMB 2.867 billion, and RMB 3.178 billion for 2025-2027, with adjusted net profits of RMB 282 million, RMB 325 million, and RMB 376 million

Huachuang Securities: Maintains "Recommended" rating for JXR with a target price of HKD 3.23

According to the latest information from the Hong Kong Stock Exchange, on September 5th, HRC Investment Holding, LLC reduced its holdings in JXR by 8.6315 million shares, at a price of HKD 2.8171 per share, for a total amount of HKD 24.3158 million. After the reduction, the latest number of shares held is approximately 134 million, with a latest holding ratio of 4.86%

HRC Investment Holding, LLC reduced its holdings in JXR by 8.6315 million shares at a price of approximately HKD 2.82 per share

Citi released a research report stating that it has lowered the revenue forecast for JXR for 2025 to 2027 by 12% to 20%, and the net profit forecast by 27% to 31%. It expects a net loss in 2025 to reflect the performance in the first half of 2025 and a cautious outlook for 2025. Based on the revised forecasts and a higher target price-to-earnings ratio, the target price has been lowered from HKD 3.8 to HKD 3.5. Citi noted that JXR's revenue decreased by 11% in the first half of this year, resulting in a net loss of RMB 1 billion, mainly due to impairment of overseas assets. The company believes that all headwinds have dissipated in the first half of the year and expects an improvement in the second half compared to the first half. Citi holds a neutral outlook for JXR in 2025 but expects it to get back on track in 2026 to 2027. According to the revised forecasts, Citi expects JXR's revenue to decline by 4% year-on-year in 2025, rebound by 10% in 2026, and continue to rise by 14% in 2027

Citi: Lowers JXR target price to HKD 3.5, expects to return to normal in the next two years

MB-JXR @EC2603A(20424.HK)

Goldman Sachs: The mainland medical sector will rely more on data and profit visibility this year, optimistic about CDMO companies

HRC Fertility expands to Las Vegas with new office led by Dr. Bradford Kolb, offering world-class fertility care.

CICC Remains a Buy on Jinxin Fertility Group Ltd. (1951)

Brief News: Although there are improvements in the fourth quarter data, JXR's annual business still fell by 1.4%

Morning Trend | JXR's capital withdrawal, is defensive sentiment intensifying under weak fluctuations?